Patents Assigned to Krystal Biotech, Inc.
-
Patent number: 11918660Abstract: The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding an immunomodulatory polypeptide (e.g., a pro-inflammatory cytokine such as a human IL-2 or IL-12 polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for the treatment of cancer, such as lung cancer); and articles of manufacture or kits thereof.Type: GrantFiled: March 8, 2023Date of Patent: March 5, 2024Assignee: Krystal Biotech, Inc.Inventors: Suma Krishnan, Trevor Parry, Dana Michelle Previte, Mary Jane Duermeyer
-
Patent number: 11865148Abstract: Provided herein are methods of delivering transgenes to an eye of a subject comprising the use of pharmaceutical compositions having one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of the transgene in the eye. Also provided herein are methods of correcting vision loss in a subject in need thereof comprising the use of the pharmaceutical compositions described herein.Type: GrantFiled: November 30, 2022Date of Patent: January 9, 2024Assignee: Krystal Biotech, Inc.Inventor: Suma Krishnan
-
Publication number: 20230414686Abstract: The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. The present disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.Type: ApplicationFiled: June 27, 2023Publication date: December 28, 2023Applicant: Krystal Biotech, Inc.Inventors: Suma KRISHNAN, Pooja AGARWAL
-
Publication number: 20230338583Abstract: The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding an immunomodulatory polypeptide (e.g., a pro-inflammatory cytokine such as a human IL-2 or IL-12 polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for the treatment of cancer, such as lung cancer); and articles of manufacture or kits thereof.Type: ApplicationFiled: May 12, 2023Publication date: October 26, 2023Applicant: Krystal Biotech, Inc.Inventors: Suma KRISHNAN, Trevor PARRY, Dana Michelle PREVITE, Mary Jane DUERMEYER
-
Publication number: 20230338444Abstract: The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a transglutaminase (TGM) polypeptide (e.g., a Transglutaminase-1 (TGM1) polypeptide); viruses comprising the recombinant nucleic acids; compositions comprising the recombinant nucleic acids and/or viruses; methods of their use; and articles of manufacture or kits thereof.Type: ApplicationFiled: June 15, 2023Publication date: October 26, 2023Applicant: Krystal Biotech, Inc.Inventors: Suma KRISHNAN, Pooja AGARWAL, John C. FREEDMAN, Mark E. O'MALLEY, Lauren K. REGULA
-
Patent number: 11779660Abstract: The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding an immunomodulatory polypeptide (e.g., a pro-inflammatory cytokine such as a human IL-2 or IL-12 polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for the treatment of cancer, such as lung cancer); and articles of manufacture or kits thereof.Type: GrantFiled: April 1, 2022Date of Patent: October 10, 2023Assignee: Krystal Biotech, Inc.Inventors: Suma Krishnan, Trevor Parry, Dana Michelle Previte, Mary Jane Duermeyer
-
Patent number: 11717547Abstract: The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a transglutaminase (TGM) polypeptide (e.g., a Transglutaminase-1 (TGM1) polypeptide); viruses comprising the recombinant nucleic acids; compositions comprising the recombinant nucleic acids and/or viruses; methods of their use; and articles of manufacture or kits thereof.Type: GrantFiled: January 3, 2020Date of Patent: August 8, 2023Assignee: Krystal Biotech, Inc.Inventors: Suma Krishnan, Pooja Agarwal, John C. Freedman, Mark E. O'Malley, Lauren K. Regula
-
Publication number: 20230241251Abstract: The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding an immunomodulatory polypeptide (e.g., a pro-inflammatory cytokine such as a human IL-2 or IL-12 polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for the treatment of cancer, such as lung cancer); and articles of manufacture or kits thereof.Type: ApplicationFiled: March 8, 2023Publication date: August 3, 2023Applicant: Krystal Biotech, Inc.Inventors: Suma KRISHNAN, Trevor PARRY, Dana Michelle PREVITE, Mary Jane DUERMEYER
-
Publication number: 20230218691Abstract: The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a polypeptide; viruses comprising the recombinant nucleic acids; compositions comprising the recombinant nucleic acids and/or viruses; methods of their use; and articles of manufacture or kits thereof.Type: ApplicationFiled: March 22, 2023Publication date: July 13, 2023Applicant: Krystal Biotech, Inc.Inventors: Pooja AGARWAL, Suma KRISHNAN, John C. FREEDMAN
-
Publication number: 20230149486Abstract: The present disclosure relates, in part, to methods of delivering transgenes to an eye of a subject comprising the use of pharmaceutical compositions having one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of transgene expression in the eye. The present disclosure also relates, in part, to methods of correcting vision loss in a subject in need thereof comprising the use of the pharmaceutical compositions described herein.Type: ApplicationFiled: November 30, 2022Publication date: May 18, 2023Applicant: Krystal Biotech, Inc.Inventors: Suma KRISHNAN, Pooja AGARWAL
-
Patent number: 11642384Abstract: The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a Serine Protease Inhibitor Kazal-type (SPINK) polypeptide (e.g., a SPINK5 polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for the treatment of Netherton Syndrome); and articles of manufacture or kits thereof.Type: GrantFiled: July 22, 2022Date of Patent: May 9, 2023Assignee: Krystal Biotech, Inc.Inventors: Pooja Agarwal, Suma Krishnan, John C. Freedman
-
Publication number: 20230118087Abstract: The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding an ichthyosis-associated polypeptide; viruses comprising the recombinant nucleic acids; compositions comprising the recombinant nucleic acids and/or viruses; methods of their use; and articles of manufacture or kits thereof.Type: ApplicationFiled: September 2, 2020Publication date: April 20, 2023Applicant: Krystal Biotech, Inc.Inventors: Suma KRISHNAN, Pooja AGARWAL
-
Publication number: 20220409685Abstract: The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a Serine Protease Inhibitor Kazal-type (SPINK) polypeptide (e.g., a SPINK5 polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for the treatment of Netherton Syndrome); and articles of manufacture or kits thereof.Type: ApplicationFiled: July 22, 2022Publication date: December 29, 2022Applicant: Krystal Biotech, Inc.Inventors: Pooja AGARWAL, Suma KRISHNAN, John C. FREEDMAN
-
Publication number: 20220323613Abstract: The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding an immunomodulatory polypeptide (e.g., a pro-inflammatory cytokine such as a human IL-2 or IL-12 polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for the treatment of cancer, such as lung cancer); and articles of manufacture or kits thereof.Type: ApplicationFiled: April 1, 2022Publication date: October 13, 2022Applicant: Krystal Biotech, Inc.Inventors: Suma KRISHNAN, Trevor PARRY, Dana Michelle PREVITE, Mary Jane DUERMEYER
-
Publication number: 20220273737Abstract: The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. The present disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.Type: ApplicationFiled: November 17, 2021Publication date: September 1, 2022Applicant: Krystal Biotech, Inc.Inventors: Suma KRISHNAN, Pooja AGARWAL
-
Publication number: 20210395775Abstract: The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a laminin polypeptide (e.g., a human laminin polypeptide) and/or a filaggrin polypeptide (e g , a human filaggrin polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for the treatment of Junctional Epidermolysis Bullosa); and articles of manufacture or kits thereof.Type: ApplicationFiled: September 25, 2019Publication date: December 23, 2021Applicant: Krystal Biotech, Inc.Inventors: Suma KRISHNAN, Pooja AGARWAL, Trevor PARRY
-
Patent number: 11185564Abstract: The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. The present disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.Type: GrantFiled: October 10, 2019Date of Patent: November 30, 2021Assignee: Krystal Biotech, Inc.Inventors: Suma Krishnan, Pooja Agarwal
-
Publication number: 20210261649Abstract: The present disclosure provides recombinant nucleic acids (e.g., recombinant herpes viral genomes) comprising one or more polynucleotides encoding an antibody; viruses (e.g., herpes viruses) comprising the recombinant nucleic acids; compositions comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for localized, virus-mediated delivery and expression of the encoded antibody); and articles of manufacture or kits thereof.Type: ApplicationFiled: June 28, 2019Publication date: August 26, 2021Applicant: Krystal Biotech, Inc,Inventors: Trevor PARRY, Pooja AGARWAL, Suma KRISHNAN
-
Publication number: 20210189427Abstract: The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a polypeptide (e.g., an inhaled therapeutic polypeptide, such as a human alpha-1-antitrypsin polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for delivering the polypeptide to one or more cells of the respiratory tract and/or for the treatment of a disease affecting the lungs, such as alpha-1-antitrypsin deficiency); and articles of manufacture or kits thereof.Type: ApplicationFiled: December 18, 2020Publication date: June 24, 2021Applicant: Krystal Biotech, Inc.Inventors: Suma KRISHNAN, Trevor Parry, Pooja Agarwal, Sara Artusi, Mladen Yovchev
-
Publication number: 20210087245Abstract: The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide (e.g., a human CFTR polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for the treatment of a chronic lung disease, such as cystic fibrosis); and articles of manufacture or kits thereof.Type: ApplicationFiled: November 6, 2020Publication date: March 25, 2021Applicant: Krystal Biotech, Inc.Inventors: Trevor PARRY, Suma KRISHNAN, Pooja AGARWAL